Skip to Main Content

Students at UCLA are calling on the university to ease access to a prostate cancer drug developed on campus.

The drug, Xtandi, is at the center of a legal battle in India over whether generic competitors can enter the market — a battle in which, students say, the university is on the wrong side.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!